(Q45295447)

English

Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial

scientific article published in January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 December 2017

Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial (English)

1 reference

Europe PubMed Central

11 December 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

insulin glargine

1 reference

based on heuristic

inferred from title

author name string

M Nauck

1

1 reference

Europe PubMed Central

11 December 2017

E Horton

2

1 reference

Europe PubMed Central

11 December 2017

M Andjelkovic

3

1 reference

Europe PubMed Central

11 December 2017

F J Ampudia-Blasco

4

1 reference

Europe PubMed Central

11 December 2017

C T Parusel

5

1 reference

Europe PubMed Central

11 December 2017

M Boldrin

6

1 reference

Europe PubMed Central

11 December 2017

R Balena

7

1 reference

Europe PubMed Central

11 December 2017

T-emerge 5 Study Group

8

1 reference

Europe PubMed Central

11 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2013

1 reference

Europe PubMed Central

11 December 2017

Diabetic Medicine

1 reference

Europe PubMed Central

11 December 2017

30

1 reference

Europe PubMed Central

11 December 2017

1

1 reference

Europe PubMed Central

11 December 2017

109-113

1 reference

Europe PubMed Central

11 December 2017

Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FDME.12003

21 January 2018

Identifiers

10.1111/DME.12003

1 reference

Europe PubMed Central

11 December 2017

1 reference

Europe PubMed Central

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45295447&oldid=2074081867"